Originally spun out of UC Santa Barbara, CytomX Therapeutics Inc (Nasdaq:CTMX) - fka Cytomx LLC - is a different kind of clinical-stage biopharmaceutical companyfocused on radically changing the way cancer is treated through development of next generation of highly targeted antibody therapeutics. With a very limited SBIR involvement, the firm is structured around changing the treatment of cancer with the firm's novel Probody therapeutic platform, the effort is to transform lives with safer, more effective therapies. CytomX has strategic drug discovery and development collaborations with AbbVie, Amgen, Astellas, and Bristol Myers Squibb. The firm's clinical-stage pipeline includes potentially first-in-class product candidates against previously undruggable targets, including a CD166-targeting Probody drug conjugate wholly owned by CytomX (CX-2009) and a CD71-targeting Probody drug conjugate partnered with AbbVie (CX-2029). CD166 and CD71 are among cancer targets that are considered to be inaccessible to conventional antibody-drug conjugates due to their presence on many healthy tissues. The CytomX clinical-stage pipeline also includes cancer immunotherapeutic candidates against validated targets such as the CTLA-4-targeting Probody therapeutics, BMS-986249 and BMS-986288, partnered with Bristol Myers Squibb, and its wholly-owned anti-PD-L1 Probody therapeutic, CX-072.
